Developments in Tissue Engineered and Regenerative Medicine Products: A Practical Approach

Developments in Tissue Engineered and Regenerative Medicine Products: A Practical Approach

Volumn , Issue , 2012, Pages 1-204

  Basu, Joydeep ^a   Ludlow, John W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864235398     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9781908818119     Document Type: Book

References (310)

1. Lee M.H., Arcidiacono J.A., Bilek A.M., et al. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States. Tissue Engng Part B 2010, 16(1):41-54.
2. About the Center for Biologics Evaluation and Research. http://www.fda.gov/AboutFDA/CentersOffices/CBER/default.htm.
3. About the Center for Devices and Radiological Health. http://www.fda.gov/AboutFDA/CentersOffices/CDRH/default.htm.
4. About the Center for Drug Evaluation and Research. http://www.fda.gov/AboutFDA/CentersOffices/CDER/default.htm.
5. ADME-Tox-Definition. http://www.wordiq.com/definition/ADME-Tox.
6. Røsland G.V., Svendsen A., Torsvik A., et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009, 69(13):5331-5339.
7. Martín-Antonio B., Granell M., Urbano-Ispizua A. Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation. Expert Rev Hematol 2010, 3(4):411-427.
8. Topics Under Harmonization. http://www.ich.org/about/organisation-of-ich/coopgroup/pandrh/topics-under-harmonisation/article/good-clinical-practices.html.
9. Glossary of Clinical Trial Terms. http://clinicaltrials.gov/ct2/info/glossary.
10. Type of clinical trials. http://www.ncbi.nlm.nih.gov/books/NBK13755/.
11. Good Clinical Practice (GCP) Regulations, Resources, & Links. http://www.regulatorypro.us/gcp/gcp_info.htm.
12. CFR - Code of Federal Regulations Title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=312.
13. Statement of investigator. http://www.cdc.gov/vaccines/vpd-vac/diphtheria/dat/downloads/inves-state-fda-1572.pdf.
14. CFR - Code of Federal Regulations, part 312 - investigational new drug application, subpart A-General provisions, Section 312.3 Definitions and interpretations. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.3.
15. Top contract research organization. http://www.jazdhealthcare.com/healthtech/leaf/Health-Information/Clinical-Research/Contract-Research-Organizations-CROs.htm.
16. Overcoming Cost Escalation with Design and Construction Strategies. http://www.tradelineinc.com/reports/CCDDBD31-2B3B-B525-8E9C98EBAD6AE55F.
17. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
18. Jiang Y., Vaessen B., Lenvik T., Blackstad M., Reyes M., Verfaillie C.M. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle and brain. Exp Hematol 2002, 30:896-904.
19. Pittenger M.F. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004, 95:9-20.
20. Van Bokkelen G. Company profile: Athersys. Regen Med 2011, 6:39-43.
21. Allison M. Genzyme backs Osiris, despite Prochymal flop. Nat Biotech 2009, 27:966-967.
22. http://www.clinicaltrials.gov/ct2/show/NCT01217008?term=geron&rank=11.
23. Keirstead H.S., Nistor G., Bernal G., et al. Human embryonic stem cell derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005, 25:4694-4705.
24. Rossi S.L., Nistor G., Wyatt T., et al. Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord. PloS One 2010, 5:e11852.
25. Montzka K., Lassonczyk N., Tschöke B., et al. Neural differentiation potential of human bone-marrow derived mesenchymal stromal cells: misleading marker gene expression. BMC Neurosci 2009, 10:16.
26. Lu B., Malcuit C., Wang S., et al. Long term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 2009, 27:2126-2135.
27. http://www.clinicaltrials.gov/ct2/show/NCT01345006?term=advanced+cell+macular&rank=2.
28. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2007, 418:41-49.
29. Aldhous P. Briefing: anatomy of a stem cell controversy. New Scientist 2008, 14:56.
30. Prockop D. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths and changing paradigms. Mol Ther 2009, 17:939-946.
31. Camussi G., Deregibus M.C., Bruno S., Cantaluppi V., Biancone L. Exosomes/microvesicles as a mechanism of cell/cell communication. Kidney Int 2010, 78:838-848.
32. Aliotta J.M., Sanchez-Guijo F.M., Dooner G.J., et al. Alteration of marrow cell gene expression, protein production and engraftment into lung by lung derived micro-vesicles: a novel mechanism for phenotype modulation. Stem Cells 2007, 25:2245-2256.
33. Baer P.C., Bereiter-Hahn J., Missler C., et al. Conditioned medium from renal tubular epithelial cells initiates differentiation of human mesenchymal stem cells. Cell Prolif 2009, 42:29-37.
34. Mack G.S. Cephalon splashes out on mesenchymal stem cells. Nature Biotechnol 2011, 29:97.
35. http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm.
36. http://neurology.emory.edu/ALS/Stem%20Cell.html.
37. http://www.reneuron.com/news/48-reneuron-gives-update-on-stroke-clinical-trial.
38. Stadtfeld M., Hocheldinger K. Induced pluripotency: history, mechanisms and applications. Genes Devel 2010, 24:2239-2263.
39. Ben-David U., Benvenisty N., Mayshar Y. Genetic instability in human induced pluripotent stem cells: classification of causes and possible safeguards. Cell Cycle 2010, 9:4603-4604.
40. www.ipierian.com.
41. Basu J., Willard H.F. Artificial and engineered chromosomes: non-integrating vectors for gene therapy. Trends Mol Med 2005, 11:251-258.
42. Sheridan C. Gene therapy finds its niche. Nat Biotechnol 2011, 29:121-128.
43. TAM transgene silencing in a genetically modified human neural stem cell line implanted into MCAo rodent brain. BMC Neurosci 2009, 10:86.
44. Basu J., Ludlow J.W. Platform technologies for tubular organ regeneration. Trends Biotechnol 2010, 28:526-533.
45. Macchiarini P., Jungebluth P., Go T., et al. Clinical transplantation of a tissue engineered airway. Lancet 2008, 372:2023-2030.
46. Oh S.K., Choo A.B. Human embryonic stem cell technology: large scale cell amplification and differentiation. Cytotechnology 2006, 50:181-190.
47. Little M.H., Rae F.K. Potential cell therapies for renal disease: can we translate results from animal studies to the human condition. Nephrology 2009, 14:544-553.
48. Sagrinati C., Ronconi E., Lazzeri E., Lasagni L., Romagnani P. Stem cell approaches for kidney repair: choosing the right cells. Trends Mol Med 2008, 14:277-285.
49. Kelley R., Werdin E.S., Bruce A.T. Tubular cell enriched subpopulation of primary renal cells improves survival and augments kidney function in rodent model of chronic kidney disease. Am J Physiol Renal Physiol 2010, F1026.
50. Presnell S.C., Bruce A.T., Wallace S.M., et al. Isolation, characterization, and expansion methods for defined primary renal cell populations from rodent, canine, and human normal and diseased kidneys. Tiss Eng Part C Methods 2011, 17:261-273.
51. http://organogenesis.com/products/bioactive_woundhealing/apligraf.html.
52. Karnik S.K., Brooke B.S., Bayes-Genis A., et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003, 130:411-423.
53. Dahl S.L., Rhim C., Song Y.C., Niklason L.E. Mechanical properties and compositions of tissue engineered and native arteries. Ann Biomed Eng 2007, 35:348-355.
54. Opitz F., Schenke-Layland K., Cohnert T.U., et al. Tissue engineering of aortic tissue: dire consequence of suboptimal elastic fiber synthesis in vivo. Cardiovascular Res 2004, 63:719-730.
55. Chun S.Y., Lim G.J., Kwon T.G., et al. Identification and characterization of bioactive factors in bladder submucosa matrix. Biomaterials 2007, 28:4251-4256.
56. http://www.mirm.pitt.edu/programs/clinical_translation/fingertip_therapy.asp.
57. Sahoo S., Ang L.T., Goh J.C., Toh S.L. Growth factor delivery through electrospun nanofibers in scaffolds for tissue engineering applications. J Biomed Mater Res A 2010, 93:1539-1550.
58. Basu J., Ludlow J.W. Platform technologies for tubular organ regeneration. Trends Biotechnol 2010, 28:526-533.
59. Petersen T.H., Calle E.A., Zhao L., et al. Tissue engineered lungs for in vivo implantation. Science 2010, 329:528-541.
60. Ott H.C., Clippinger B., Conrad C., et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010, 16:927-933.
61. Macchiarini P., Jungebluth P., Go T., et al. Clinical transplantation of a tissue-engineered airway. Lancet 2008, 372:2023-2030.
62. Crapo P.M., Gilbert T.W., Badylak S.F. An overview of tissue and whole organ decellularization processes. Biomaterials 2011, 32:3233-3243.
63. Harnden I., Kiernan K., Kearns-Jonker M. The anti-nonGal xenoantibody response to alpha1, 3-galactosyltransferase gene knockout pig xenografts. Curr Opin Organ Transplant 2010, 15:207-211.
64. Bonventre J.V. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003, 14:S55-S61.
65. Guo J.K., Cantley L.G. Cellular maintenance and repair of the kidney. Ann Rev Physiol 2010, 72:357-376.
66. Lin F., Moran A., Igarashi P. Intra-renal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest 2005, 115:1756-1764.
67. Kelley R., Werdin ES., Bruce AT. Bioactive renal cells augment kidney function in a rodent model of chronic kidney disease 2010, http://www.tengion.com/news/documents/Kelley%202010%20ISCT%20podium%20FINAL.pdf.
68. Kelley R., Werdin E.S., Bruce A.T., et al. A tubular cell-enriched subpopulation of primary renal cells improves survival and augments kidney function in a rodent model of chronic kidney disease. Am J Physiol Renal Physiol 2010, 299:F1026-F1039.
69. Presnell S.C., Bruce A.T., Wallace S.M., et al. Isolation, characterization, and expansion (ICE) methods for defined primary renal cell populations from rodent, canine, and human normal and diseased kidneys. Tissue Eng Part C Methods 2010, 17:261-273.
70. Hunt N.C., Grover L.M. Cell encapsulation using biopolymer gels for regenerative medicine. Biotechnol Lett 2010, 32:733-742.
71. Rosines E., Schmidt H.J., Nigam S.K. The effect of hyaluronic acid size and concentration on branching morphogenesis and tubule differentiation in developing kidney culture systems: potential applications to engineering of renal tissues. Biomaterials 2007, 28:4806-4817.
72. Bible E., Chau D.Y., Alexander M.R., Price J., Shakesheff K.M., Modo M. The support of neural stem cells transplanted into stroke-induced brain cavities by PLGA particles. Biomaterials 2009, 30:2985-2994.
73. Basu J., Genheimer C.W., Rivera E.A., et al. Functional evaluation of primary renal cell/biomaterial Neo-Kidney Augment prototypes for renal tissue engineering. Cell Transplantation doi: 2011, 10.3727/096368911X566172.
74. Yang B., Zhang Y., Zhou L., et al. Development of a porcine bladder acellular matrix with well preserved extracellular bioactive factors for tissue engineering. Tissue Eng Part C 2010, 16:1201-1211.
75. Piechota H.J., Gleason C.A., Dahms S.E., et al. Bladder acellular matrix graft: in vivo functional properties of the regenerated rat bladder. Urol Res 1999, 27:206-213.
76. Zhang Y., Frimberger D., Cheng E.Y., Lin H.K., Kropp B.P. Challenges in a larger bladder replacement with cell-seeded and unseeded small intestinal submucosa grafts in a subtotal cystectomy model. BJU Int 2006, 98:1100-1105.
77. Caione P., Capozza N., Zavaglia D., Palombaro G., Boldrini R. In vivo bladder regeneration using small intestinal submucosa: experimental study. Pediatr Surg Int 2006, 22:593-599.
78. Basu J., Genheimer C.W., Guthrie K.I., et al. Expansion of the human adipose derived stromal vascular cell fraction yields a population of smooth muscle like cells with markedly distinct phenotypic and functional properties relative to mesenchymal stem cells. Tissue Eng Part C 2011, 17:843-860.
79. Basu J., Mihalko K.L., Payne R., et al. Extension of bladder based organ regeneration platform for tissue engineering of esophagus. Med Hypotheses 2012, 78:231-234.
80. http://www.tengion.com/pdfs/Ludlow-2010-TERMIS-SI-poster-FINAL.pdf.
81. Basu J., Mihalko K.L., Payne R., et al. Regeneration of rodent small intestine tissue following implantation of scaffolds seeded with a novel source of smooth muscle cells. Regen Med 2011, 6:721-731.
82. http://www.medicinenet.com/bladder_cancer/page2.htm.
83. http://www.uihealthcare.com/topics/medicaldepartments/urology/bladderstones/index.html.
84. Gurocak S., Nuininga J., Ure I., De Gier R.P., Tan M.O., Feitz W. Bladder augmentation: review of the literature and recent advances. Indian J Urol 2007, 23:452-457.
85. Neuhof H. Fascial transplantation into visceral defects: an experimental and clinical study. Surg Gynecol Obst 1917, 25:383.
86. Atala A., Vacanti J.P., Peters C.A., Mandell J., Retik A.B., Freeman M.R. Formation of urothelial structures in vivo from dissociated cells attached to biodegradable polymer scaffolds in vitro. J Urol 1992, 148:658-662.
87. Atala A., Freeman M.R., Vacanti J.P., Shepard J., Retik A.B. Implantation in vivo and retrieval of artificial structures consisting of rabbit and human urothelium and human bladder muscle. J Urol 1993, 150:608-612.
88. Cilento B.G., Freeman M.R., Schneck F.X., Retik A.B., Atala A. Phenotypic and cytogenetic characterization of human bladder urothelia expanded in vitro. J Urol 1994, 152:665-670.
89. Litbarg N.O., Gudehithlu K.P., Sethupathi P., Arruda J.A., Dunea G., Singh A.K. Activated omentum becomes rich in factors that promote healing and tissue regeneration. Cell Tissue Res 2007, 328:487-497.
90. Oberpenning F., Meng J., Yoo J.J., Atala A. De novo reconstitution of a functional mammalian urinary bladder by tissue engineering. Nature Biotechnol 1999, 17:149-155.
91. Jayo M.J., Jain D., Wagner B.J., Bertram T.A. Early cellular and stromal responses in the regeneration of a functional mammalian bladder. J Urol 2008, 180:392-397.
92. Jayo M.J., Jain D., Ludlow J.W., et al. Long-term durability, tissue regeneration and neo-organ growth during skeletal maturation with a neobladder augmentation construct. Regen Med 2008, 3:671-682.
93. Lai J.Y., Yoon C.Y., Yoo J.J., Wulf T., Atala A. Phenotypic and functional characterization of in vivo tissue engineered smooth muscle from normal and pathological bladders. J Urol 2002, 168:1853-1858.
94. Atala A., Bauer S.B., Soker S., Yoo J.J., Retik A.B. Tissue engineered autologous bladders for patients needing cystoplasty. Lancet 2006, 306:1241-1246.
95. Genheimer C.W., Guthrie K.I., Shokes J.E., et al. Increased urothelial cell detection in the primary bladder smooth muscle cell cultures with dual MACs/qRT-PCR approach. Appl Immunohistochem Mol Morphol 2010, 19:184-189.
96. Metharom P., Liu C., Wang S., Stalboerger P., et al. Myeloid lineage of high proliferative potential human smooth muscle outgrowth cells circulating in blood and vasculogenic smooth muscle-like cells in vivo. Atherosclerosis 2008, 198:29-38.
97. He Q., Wan C., Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells 2007, 25:69-77.
98. Basu J., Genheimer C.W., Guthrie K.I., et al. Expansion of the human adipose-derived stromal vascular cell fraction yields a population of smooth muscle-like cells with markedly distinct phenotypic and functional properties relative to mesenchymal stem cells. Tissue Eng Part C, Methods 2011, 17:843-860.
99. Jack G.S., Zhang R., Lee M., Xu Y., Wu B.M., Rodriguez L.V. Urinary bladder smooth muscle engineered from adipose stem cells and a three dimensional synthetic composite. Biomaterials 2009, 30:3259-3270.
100. Gong Z., Calkins G., Cheng E.C., Krause D., Niklason L.E. Influence of culture medium on smooth muscle cell differentiation from human bone marrow derived mesenchymal stem cells. Tissue Eng Part A 2009, 15:319-330.
101. Kim Y.M., Jeon E.S., Kim M.R., Lee J.S., Kim J.H. Bradykinin-induced expression of alpha-smooth muscle actin in human mesenchymal stem cell. Cell Signal 2008, 20:1882-1889.
102. Jeon E.S., Moon H.J., Lee M.J., et al. Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth muscle like cells through a TGF-beta dependant mechanism. J Cell Sci 2006, 119:4994-5005.
103. Kim Y.M., Jeon E.S., Kim M.R., Jho S.K., Ryu S.W., Kim J.H. Angiotensin II-induced differentiation of adipose tissue derived mesenchymal stem cells to smooth muscle cells. Int J Biochem Cell Biol 2008, 40:2482-2491.
104. Xu W., Zhang X., Qian H., et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med 2004, 229:623-631.
105. Sakuma T., Matsumoto T., Kano K., et al. Mature, adipocyte derived, dedifferentiated fat cells can differentiate into smooth muscle like cells and contribute to bladder tissue regeneration. J Urol 2009, 182:355-365.
106. Kanematsu A., Yamamoto S., Iwai-Kanai E., et al. Induction of smooth muscle cell like phenotype in marrow derived cells among regenerating urinary bladder smooth muscle cells. Am J Pathol 2005, 166:565-573.
107. Becker C., Laeufer T., Arikkat J., Jakse G. TGFbeta1 and epithelialmesenchymal interactions promote smooth muscle gene expression in bonemarrow stromal cells: possible application in therapies for urological defects. Int J Artif Organs 2008, 31:951-959.
108. Basu J., Genheimer C.W., Rivera E.A., et al. Functional evaluation of primary renal cell/biomaterial Neo-Kidney Augment prototypes for renal tissue engineering. Cell Transplant doi: 2011, 10.3727/096368911X566172.
109. Campbell J.H., Efendy J.L., Campbell G.R. Novel vascular graft grown within recipient's own peritoneal cavity. Circ Res 1999, 85:1173-1178.
110. Campbell G.R., Turnbull G., Xiang L., et al. The peritoneal cavity as a bioreactor for tissue engineering visceral organs: bladder, uterus and vas deferens. J Tissue Eng Regen Med 2008, 2:50-60.
111. http://my.clevelandclinic.org/services/urinary_reconstruction_and_diversion/hic_urinary_reconstruction_and_diversion.aspx.
112. Basu J., Genheimer C.W., Guthrie K.I., et al. Expansion of the human adipose-derived stromal vascular cell fraction yields a population of smooth muscle like cells with markedly distinct phenotypic and functional properties relative to mesenchymal stem cells. Tissue Eng Part C, Methods 2011, 17:843-860.
113. Zhang F., Tsai S., Kato K., et al. Transforming growth factor beta promotes recruitment of bone marrow cells and bone marrow derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J Biol Chem 2009, 284:17564-17574.
114. http://www.tengion.com/pdfs/ISSCR-poster-final.pdf.
115. Jayo M.J., Jain D., Wagner B.J., Bertram T.A. Early cellular and stromal responses in the regeneration of a functional mammalian bladder. J Urol 2008, 180:392-397.
116. Jayo M.J., Jain D., Ludlow J.W., et al. Long-term durability, tissue regeneration and neo-organ growth during skeletal maturation with a neo-bladder augmentation construct. Regen Med 2008, 3:671-682.
117. http://www.clinicaltrials.gov/ct2/show/NCT01087697?term=tengion&rank=3.
118. http://www.tengion.com/pdfs/Jayo-2010-TERMIS-poster-FINAL.pdf.
119. Atala A., Bauer S.B., Soker S., Yoo J.J., Retik A.B. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 2006, 367:1241-1246.
120. Asnaghi M.A., Jungebluth P., Raimondi M.T., et al. A double-chamber rotating bioreactor for the development of tissue engineered hollow organs: from concept to clinical trial. Biomaterials 2009, 30:5260-5269.
121. Macchiarini P., Jungebluth P., Go T., et al. Clinical transplantation of a tissue-engineered airway. Lancet 2008, 372:2023-2033.
122. http://www.americanheart.org.
123. Hibino N., McGillicuddy E., Matsumura G., et al. Late term results of tissue engineered vascular grafts in humans. J Thorac Cardiovasc Surg 2010, 139:431-436.
124. Ravi S., Chaikof E.L. Biomaterials for vascular tissue engineering. Regen Med 2010, 5(1):107-120.
125. Dahl S.L., Kypson A.P., Lawson J.H., et al. Readily available tissueengineered vascular grafts. Science Trans Med 2011, 3:1-10.
126. McAllister T.N., Maruszewski M., Garrido S.A., et al. Effectiveness of hemodialysis access with an autologous tissue engineered vascular graft: a multicentre cohort study. Lancet 2009, 373:1440-1446.
127. Wystrychowski W., Cierpka L., Zagalski K., et al. Case study: first implantation of a frozen, devitalized tissue-engineered vascular graft for urgent hemodialysis access. J Vasc Access 2011, 12:67-70.
128. Wang C., Cen L., Yin S., et al. A small diameter elastic blood vessel wall prepared under pulsatile conditions from polyglycolic acid mesh and smooth muscle cells differentiated from adipose derived stem cells. Biomaterials 2010, 31:621-630.
129. Gong Z., Niklason L.E. Small diameter human vessel wall engineered from bone marrow derived mesenchymal stem cells (hMSCs). FASEB J 2008, 22:1635-1648.
130. Basu J., Genheimer C.W., Guthrie K.I., et al. Expansion of the human adipose derived stromal vascular cell fraction yields a population of smooth muscle like cells with markedly distinct phenotypic and functional properties relative to mesenchymal stem cells. Tissue Eng Part C Methods 2011, 17:843-860.
131. Shigemura N., Okumura M., Mizuno S., et al. Lung tissue engineering technique with adipose stromal cells improves surgical outcome for pulmonary emphysema. Am J Respir Crit Care Med 2006, 174:1199-1205.
132. Andrade C.F., Wong A.P., Waddell T.K., Keshavjee S., Liu M. Cell based tissue engineering for lung regeneration. Am J Physiol Lung Cell Mol Physiol 2007, 292:L510-L518.
133. Mondrinos M.J., Koutzaki S., Jiwanmall E., et al. Engineering three dimensional pulmonary tissue constructs. Tissue Eng 2006, 12:717-728.
134. Mondrinos M.J., Koutzaki S., Lelkes P.I., Finck C.M. A tissue engineered model of fetal distal lung tissue. Am J Physiol Lung Cell Mol Physiol 2007, 293:L639-L650.
135. Ott H.C., Clippinger B., Conrad C., et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010, 16:927-933.
136. Petersen T.H., Calle E.A., Zhao L., et al. Tissue-engineered lungs for in vivo implantation. Science 2010, 329:538-541.
137. Cortiella J., Niles J., Cantu A., et al. Influence of acellular natural lung matrix on murine embryonic stem cell differentiation and tissue formation. Tissue Eng Part A 2010, 16:2565-2580.
138. http://digestive.niddk.nih.gov/ddiseases/pubs/shortbowel/.
139. Sala F.G., Kunisaki S.M., Ochoa E.R., Vacanti J., Grikscheit T.C. Tissue engineered small intestine and stomach form from autologous tissue in a preclinical large animal model. J Surg Res 2009, 156:205-212.
140. Nakase Y., Hagiwara A., Nakamura T., et al. Tissue engineering of small intestinal tissue using collagen sponge scaffolds seeded with smooth muscle cells. Tissue Eng 2006, 12:403-412.
141. Nakase Y., Nakamura T., Kin S., et al. Endocrine cell and nerve regeneration in autologous in situ tissue engineered small intestine. J Surg Res 2007, 137:61-68.
142. Urita Y., Komuro H., Chen G., et al. Regeneration of the esophagus using gastric acellular matrix: an experimental study in a rat model. Pediatr Surg Int 2007, 23:21-26.
143. Nakase Y., Nakamura T., Kin S., et al. Intrathoracic esophageal replacement by in situ tissue engineered esophagus. J Thorac Cardiovasc Surg 2008, 136:850-859.
144. Doede T., Bondartschuk M., Joerck C., Schulze E., Goernig M. Unsuccessful alloplastic esophageal replacement with porcine small intestinal submucosa. Artificial Organs 2009, 33:328-333.
145. Araki M., Tao H., Sato T., et al. Development of a new tissue engineered sheet for reconstruction of the stomach. Artificial Organs 2009, 33:818-826.
146. Somara S., Gilmont R.R., Dennis R.G., Bitar K.N. Bioengineered internal anal sphincter derived from isolated human internal and sphincter smooth muscle cells. Gastroenterology 2009, 137:53-61.
147. Hashish M., Raghavan S., Somara S., et al. Surgical implantation of a bioengineered internal anal sphincter. J Ped Surg 2010, 45:52-58.
148. De Filippo R.E., Bishop C.E., Filho L.F., Yoo J.J., Atala A. Tissue engineering a complete vaginal replacement from a small biopsy of autologous tissue. Transplantation 2008, 86:208-214.
149. Chen K.L., Eberli D., Yoo J.J., Atala A. Bioengineered corporal tissue for structural and functional restoration of the penis. Proc Natl Acad Sci USA 2010, 107:3346-3350.
150. Raya-Rivera A., Esquiliano D.R., Yoo J.J., Lopez-Bayghen E., Soker S., Atala A. Tissue engineered autologous urethras for patients who need reconstruction: an observational study. Lancet 2011, 377:1175-1182.
151. Basu J., Ludlow J.W. Platform technologies for tubular organ regeneration. Trends Btotechnol 2010, 28(10):526-533.
152. Boudoulas K.D., Hatzopoulos A.K. Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease. Dis Model Mech 2009, 2:344-358.
153. Basu J., Ludlow J.W. Platform technologies for tubular organ regeneration. Trends Biotechnol 2010, 28:526-533.
154. Basu J., Genheimer C., O'Reilly D.D., et al. Distribution and analysis of stem and progenitor cell populations in large mammal and human kidneys. FASEB J 2010, 24:lb35.
155. The Kidney: from Normal Development to Congenital Disease 2003, Academic Press, New York. P.D. Vize, A.S. Woolf, J.B.L. Bard (Eds.).
156. Sagrinati C., Ronconi E., Lazzeri E., Lasagni L., Romagnani P. Stem-cell approaches for kidney repair: choosing the right cells. Trends Mol Med 2008, 14:277-285.
157. Hopkins C., Li J., Rae F., Little M.H. Stem cell options for kidney disease. J Pathol 2009, 217:265-281.
158. Tögel F., Yang Y., Zhang P., Hu Z., Westenfelder C. Bioluminesence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Renal Physiol 2008, 295:F315-F321.
159. Kunter U., Rong S., Boor P., et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 2007, 18:1754-1764.
160. Ross E.A., Williams M.J., Hamazaki T., et al. Embryonic stem cells proliferate and differentiate when seeded into kidney scaffolds. J Am Soc Nephrol 2009, 20:2338-2347.
161. Nakayama K.H., Batchelder C.A., Lee C.I., Tarantal A.F. Decellularized rhesus monkey kidney as a three dimensional scaffold for renal tissue engineering. Tissue Eng Part A 2010, 16:2207-2216.
162. Zhou J., Fritze O., Schleicher M., et al. Impact of heart valve decellularization on 3D ultrastructure, immunogenicity and thrombogenicity. Biomaterials 2010, 31:2549-2554.
163. Joraku A., Stern K.A., Atala A., Yoo J.J. In vitro generation of three dimensional renal structures. Methods 2009, 47:129-133.
164. Chung I.M., Enemchukwu N.O., Khaja S.D., Murthy N., Mantalaris A., Garcia A.J. Bioadhesive hydrogel microenvironments to modulate epithelial morphogenesis. Biomaterials 2008, 29:2637-2645.
165. Paliege A., Rosenberger C., Bondke A., et al. Hypoxia-inducible factor-2 alpha expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int 2010, 77:312-318.
166. Caplan A.I. Why are MSCs therapeutic? New data, new insight. J Pathol 2009, 217:318-324.
167. Roessger A., Denk L., Minuth W.W. Potential of stem/progenitor cell cultures within polyester fleeces to regenerate renal tubules. Biomaterials 2009, 30:3723-3732.
168. Minuth W.W., Denk L., Castrop H. Generation of tubular superstructures by piling of renal stem/progenitor cells. Tissue Engineering Part C 2008, 14:3-13.
169. Presnell S.C., Bruce A.T., Wallace S.M., et al. Isolation, characterization and expansion methods for defined primary renal cell populations from rodent, canine and human normal and diseased kidneys. Tissue Eng Part C 2011, 17:261-273.
170. Kelley R., Werdin E.S., Bruce A.T., et al. Tubular cell enriched subpopulation of primary renal cells improves survival and augments kidney function in rodent model of chronic kidney disease. Am J Physiol Renal Physiol 2010, 299F:1026-1039.
171. Basu J., Genheimer C.W., Rivera E.A., et al. Functional evaluation of primary renal cell/biomaterial Neo-Kidney Augment prototypes for renal tissue engineering. Cell Transplantation 2011, 10.3727/096368911X566172.
172. Jopling C., Sleep E., Raya M., Marti M., Raya A., Belmonte J.C. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 2010, 464:606-611.
173. Bicknell K.A., Coxon C.H., Brooks G. Can the cardiomyocyte cycle be reprogrammed?. J Mol Cell Cardiol 2007, 42:706-721.
174. Ott H.C., Matthiesen T.S., Goh S.K., et al. Perfusion decellularized matrix: using nature's platform to engineer a bioartificial heart. Nature Med 2008, 14:213-221.
175. Fong P.M., Park J., Breuer C.K. Heart valves. Principles of Tissue Engineering 2008, 585-587. Elsevier, Amsterdam. 3rd edn. R. Lanza, R. Langer, J. Vacanti (Eds.).
176. Lesman A., Habib M., Caspi O., et al. Transplantation of a tissue engineered human vascularized cardiac muscle. Tissue Eng Part A 2010, 16:115-125.
177. Seif-Naraghi S.B., Salvatore M.A., Schup-Magoffin P.J., Hu D.P., Christman K.L. Design and characterization of an injectable pericardial matrix gel: a potentially autologous scaffold for cardiac tissue engineering. Tissue Eng Part A 2010, 16:2017-2027.
178. Zaret K.S., Grompe M. Generation and regeneration of cells of the liver and pancreas. Science 2008, 322:1490-1494.
179. Underhill G.H., Khetani S.R., Chen A.A., et al. Liver. Principles of Tissue Engineering 2007, 707-726. Elsevier, Amsterdam. 3rd edn. R. Lanza, R. Langer, J. Vacanti (Eds.).
180. Nahmias Y., Casali M., Barbe L., Berthiaume F., Yarmush M.L. Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. Hepatology 2006, 43:257-265.
181. Takeda M., Yamamoto M., Isoda K., et al. Availability of bone marrow stromal cells in three dimensional coculture with hepatocytes and transplantation into liver damaged mice. J. Biosci Bioengng 2005, 100:77-81.
182. Zhang L., Theise N., Chua M., Reid L.M. The stem cell niche of human livers: Symmetry between development and regeneration. Hepatology 2008, 48:1598-1607.
183. Léns-Visconti R., A Bonora, R Jover Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. World J Gastroenterol 2006, 12:5834-5845.
184. Ruiz J.C., Ludlow J.W., Sherwood S., Yu G., Wu X., Gimble J.M. Differentiated human adipose derived stem cells exhibit hepatogenic capability in vitro and in vivo. J Cell Physiol. 2010, 225:429-436.
185. Tai B.C., Du C., Gao S., Wan A.C., Ying J.Y. The use of a polyelectrolyte fibrous scaffold to deliver differentiated hMSCs to the liver. Biomaterials 2009, 31:48-57.
186. Ohashi K., Yokoyama T., Yamato M., et al. Engineering functional two and three dimensional liver systems in vivo using hepatic tissue sheets. Nat Med 2007, 13:880-885.
187. Fiegel H.C., Kneser U., Kluth D., Metzger R., Till H., Rolle U. Development of hepatic tissue engineering. Pediatr Surg Int 2009, 25:667-673.
188. Juhl K., Bonner-Weir S., Sharma A. Regenerating pancreatic β-cells: plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis. Curr Opin Organ Transplant 2010, 15:79-85.
189. Cano D.A., Rulifson I.C., Heiser P.W., et al. Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes 2008, 57:958-966.
190. Sambanis A. Bioartificial pancreas. Principles of Tissue Engineering 2007, 619-630. Elsevier, Amsterdam. 3rd edn. R. Lanza, R. Langer, J. Vacanti (Eds.).
191. Lin C.C., Anseth K.S. Glucagon like peptide 1 functionalized PEG hydrogels promote survival and function of encapsulated β-cells. Biomacromolecules 2009, 10:2460-2467.
192. Su J., Hu B.H., Lowe W.L., Kaufman D.B., Messersmith P.B. Anti-inflammatory peptide-functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials 2010, 31:308-314.
193. De Carlo E., Baiguera S., Conconi M.T., et al. Pancreatic acellular matrix supports islet survival and function in a synthetic tubular device: in vitro and in vivo studies. Int J Mol Med 2010, 25:195-202.
194. Kodama S., Kojima K., Furuta S., Chambers M., Paz A.C., Vacanti C.A. Engineering functional islets from cultured cells. Tissue Eng Part A 2009, 15:3321-3329.
195. Kin T., O'Neil J.J., Pawlick R., Korbutt G.S., Shapiro A.M., Lakey J.R. The use of an approved biodegradable polymer scaffold as a solid support system for improvement of islet engraftment. Artif Organs 2008, 32:990-993.
196. Shimizu H., Ohashi K., Utoh R., et al. Bioengineering of a functional sheet of islet cell sfor treatment of diabetes mellitus. Biomaterials 2009, 30:5943-5949.
197. Grikscheit T.C., Sala F.G., Ogilvie J., et al. Tissue engineered spleen protects against overwhelming pneumococcal sepsis in a rodent model. J Surg Res 2008, 149:214-218.
198. Park J., Lim E., Back S., Na H., Park Y., Sun K. Nerve regeneration following spinal cord injury using matrix metalloproteinase-sensitive, hyaloronic acid based biomimetic hydrogel scaffold containing brain derived neurotrophic factor. J Biomed Mater Res A 2009, 93:1091-1099.
199. Zhang H., Kamiya T., Hayashi T., et al. Gelatin-siloxane hybrid scaffolds with vascular endothelial growth factor induces brain tissue regeneration. Curr Neurovasc Res 2008, 5:112-117.
200. Bible E., Chau D.Y., Alexander M.R., Price J., Shakesheff K.M., Modo M. The support of neural stem cells transplanted into stroke induced brain cavities by PLGA particles. Biomaterials 2009, 30:2985-2994.
201. Park K.S., Kim Y.S., Kim J.H., et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function and angiogenesis of isolated islets after transplantation. Transplantation 2010, 89:509-517.
202. Federal Food, Drug, and Cosmetic Act. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm.
203. ComplianceNet Inc., cGMP defined. http://www.gmpcompliance.net/CGMP_Defined/CGMP_Defined.htm.
204. Quality Management System. http://www.ehow.com/quality-management-system/.
205. Quality Assurance Management Procedures. http://www.gmpqualityup.com/.
206. What is Quality Control? . http://www.wisegeek.com/what-is-quality-control.htm.
207. GMP Guidelines. http://www.ispe.org/cs/gmp/gmp_guidelines.
208. GMP/GLP. http://www.satistar.com/expertise.php?ID=27.
209. Medicines Act of 1968. http://www.legislation.gov.uk/ukpga/1968/67.
210. What is an FDA 483? . http://www.ehow.com/facts_6883982_fda-483_html.
211. Manufacturers sought for joint FDA-EMA GMP inspection pilot. http://www.fdanews.com/newsletter/article?issueId=14070&articleId=130522.
212. Good Laboratory Practices for Non-Clinical Laboratory Studies. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58&showFR=1.
213. Good Clinical Practice (GCP) Training. http://www.cfpa.com/gcp-training/.
214. Good Tissue Practices. Products/QuestionsaboutTissues/ucm102994.htm. http://www.fda.gov/BiologicsBloodVaccines/TissueTissue.
215. Tissue guidance. RegulatoryInformation/Guidances/Tissue/default.htm. http://www.fda.gov/BiologicsBloodVaccines/GuidanceCompliance.
216. Weber DJ (2008) Understanding and implementing good tissue practices (GTPs). http://www.biologicsconsulting.com/articles/GTPs_Weber.pdf.
217. Guidance for industry: eligibility determination for donors of human cell, tissues, and cellular tissue-based products. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073964.htm.
218. Draft Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm125678.htm.
219. Draft Guidance for Industry: Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm062693.htm.
220. Draft Guidance for Industry: Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion and Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073961.htm.
221. Guidance for Industry: Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073967.htm.
222. GMP Document management System - A brief Guide. http://www.gmp-quality.com/documentation.html.
223. SOP Writing. http://www.its-ltd.co.uk/sop_writing.html.
224. How to Write a Standard Operating Procedure. http://www.ehow.com/how_2096579_write-standard-operating-procedure.html.
225. Good Manufacturing Practices. Batch Records. http://www.bio-link.org/GMP/batchdoc.html.
226. Validation and Compliance Institute. http://vcillc.com/.
227. GMP and Regulatory Updates. http://gmponblog.vinvarun.biz/.
228. U.S. FDA Title 21 CFR Part 11 Compliance Assessment of SAP® Learning Solution. http://www.sdn.sap.com/irj/scn/go/portal/prtroot/docs/library/uuid/e0c38fbf-f1d6-2a10-8a8e-bc9e593c3e98?QuickLink=index&overridelayout=true.
229. Guidance Documents. http://hc-sc.gc.ca/dhp-mps/compli-conform/gmp-bpf/docs/index-eng.php.
230. http://www.jeiven.com/GMP-GCP-SOPTraining_Programs_Brochure.pdf.
231. cGMP University Compliance Experts. http://cgmpuniversity.com/.
232. The Center for Professional Innovation and Education. http://www.cfpie.com/showitem.aspx?productid=GMPCP.
233. Occupational Safety and Health Administration. http://osha.gov/.
234. On line Bloodborne Pathogens Training. http://www.probloodborne.com/en/.
235. Bloodborne Pathogens Retraining (EHS 0738). http://www.lbl.gov/ehs/biosafety/BBP_Training/bbp_training.shtml.
236. Bloodborne Pathogens. http://www.usg.edu/ehs/training/pathogens/table.phtml.
237. Chemical Hygiene Plan and OSHA. http://www.ehow.com/info_7815520_chemical-hygiene-plan-osha.html.
238. OSHA Safety and Health Topic. Laboratories. http://www.osha.gov/SLTC/laboratories/index.html.
239. International Air Transport Association. http://www.iata.org/whatwedo/cargo/dangerous_goods/Pages/infectious_substances.aspx.
240. Transporting and Shipping Infectious Substances A and B (Updated May 17, 2010). http://www.scdhec.gov/health/lab/docs/labeling.pdf.
241. CDC Etiologic Agent Import Permit Program. http://www.cdc.gov/od/eaipp/.
242. USDA/APHIS. http://www.aphis.usda.gov/import_export/index.shtml.
243. DOC Bureau of Industry and Securities. http://www.bis.doc.gov/licensing/exportingbasics.htm.
244. Compliance on-line: The most comprehensive resource for compliance and quality. https://www.complianceonline.com/ecommerce/control/bestPractices?catId=10001&catName=Pharmaceutical.
245. ICH - harmonization for better health. http://www.ich.org/home.html.
246. E6 Guideline for Good Clinical Practices. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf.
247. Ethnic factors in the acceptability of foreign clinical data. http://www.firstclinical.com/regdocs/doc/?db=ICH_E5(R1).
248. Good manufacturing practice guidance for active pharmaceutical ingredients. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129098.pdf.
249. ICH Topic Q6A: Specifications: Test procedures and acceptance criteria for new drug substances and new drug products; Chemical substances. http://www.tga.gov.au/docs/pdf/euguide/ich/036796en.pdf.
250. ICH Topic Q6B: Specifications: Test procedures and acceptance for biotechnological/biological products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002824.pdf.
251. Impurities in new drug substances. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127984.pdf.
252. Impurities in new drug products (9); Impurities: Guideline for residual solvents. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm128033.pdf.
253. Impurities: Guideline for residual solvents. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002674.pdf.
254. Stability testing of new drug substances. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002651.pdf.
255. Photostability testing of new active substances and medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002647.pdf.
256. Common technical documents for the registration of pharmaceuticals for human use. http://www.ikev.org/haber/stabilite/kitap/41%201.13%20%20Stability%20Workshop%20ICH%20M4,%20ICH%20M4Q%20C%20.pdf.
257. The medical dictionary for regulatory activities. http://www.ich.org/products/meddra.html.
258. ICH Global Cooperation Group. http://www.ich.org/about/organisation-of-ich/coopgroup.html.
259. Asian Pacific Economic Cooperation. http://www.apec.org/.
260. List of GCC countries and nations. http://www.dubaifaqs.com/list-of-gcc-countries.php.
261. http://www.fda.gov/InternationalPrograms/HarmonizationInitiatives/ucm114628.htm.
262. South African Development Community. http://www.sadc.int/.
263. Association of Southeast Asian Nations. http://www.aseansec.org/74.htm.
264. Pharmacopoeial Discussion Group (PDG) Meeting. https://www.usp.org/USPNF/pharmacopeialHarmonization/pdgMeeting2008-06-05.html.
265. The IPEC Federation. http://ipecfed.org/.
266. Investigational new Drug (IND) Application. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm.
267. ICH GCP Investigators Brochure. http://ichgcp.org/7-investigator%e2%80%99s-brochure/.
268. Good Design Practices for GMP Pharmaceutical Facilities, edited by Andrew Signore and Terry Jacobs. https://www.chipsbooks.com/goodes.htm.
269. GMP buildings and facilities. http://www.pharmatips.doyouknow.in/Articles/Quality-Assurance/GMP/GMP-Buildings-And-Facilities.aspx.
270. International Organization for Standardization. http://www.iso.org/iso/home.html.
271. FS209E and ISO Clean room Standards. http://www.terrauniversal.com/cleanrooms/iso-classification-cleanroom-standards.html.
272. Particle counter. http://en.wikipedia.org/wiki/Particle_counter.
273. FDA process validation guidelines. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070336.pdf.
274. Qualification of raw materials for biopharmaceutical use. http://biopharminternational.findpharma.com/biopharm/article/articleDetail.jsp?id=86831.
275. Process Validation. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/QualitySystemsRegulations/MedicalDeviceQualitySystemsManual/ucm122439.htm.
276. The New Guidance: Process Validation has moved back into process development and characterization. http://www.dsinpharmatics.com/the-new-guidance-process-validation-has-moved-back-into-process-development-and-characterization/.
277. Quality Management Systems - Process Validation Guidance. http://www.ghtf.org/documents/sg3/sg3_fd_n99-10_edition2.doc.
278. Guidance for the submission of chemistry, manufacturing, and controls information and establishment description for autologous somatic cells therapy products. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM169060.txt.
279. Jayo M.J., Jain D., Ludlow J.W., Payne R., Wagner B.J., McLorie G., Bertram T.A. Long-term durability, tissue regeneration and neo-organ growth during skeletal maturation with a neo-bladder augmentation construct. Regen Med 2008, 3(5):671-682.
280. Measuring Measuring the economic impact of IP systems 2007, http://www.wipo.int/export/sites/www/about-ip/en/studies/pdf/wipo_unu_07_general.pdf.
281. method A. A method for assessing patent landscape 2010, http://nciia.org/sites/default/files/conf2010papers/anderson2_0.pdf.
282. United States Trademark and Patent Office. http://www.uspto.gov/.
283. Patent Lens. http://www.patentlens.net/daisy/patentlens/patentlens.html.
284. Easy to Use Patents Search and Patent Lawyer Directory. http://www.patents.com/.
285. Freepatentsonline all the inventions of mankind. http://www.freepatentsonline.com/.
286. Raysman R, Pisacreta EA, Adler KA. (1999-2008). Intellectual Property Licensing: Forms and Analysis. Law Journal Press.
287. Asian Patent Alliance. http://www.asiapatent.net/.
288. European Patent Office. http://www.epo.org/.
289. Patent Cooperation Treaty. http://www.wipo.int/pct/en/treaty/about.htm.
290. Disclosure Documents Discontinued. http://www.uspto.gov/web/offices/pac/disdo.html.
291. European Patent Convention. http://www.epo.org/patents/law/legal-texts/html/epc/2000/e/ar83.html.
292. 2165 The Best Mode Requirement - 2100 Patentability. http://www.uspto.gov/web/offices/pac/mpep/documents/2100_2165.htm.
293. 2164 The Enablement Requirement [R-2] - 2100 Patentability. http://www.uspto.gov/web/offices/pac/mpep/documents/2100_2164.htm.
294. In this respect, decision T 388/04 of 22 March 2006 of the Boards of Appeal of the European Patent Office has made it clear that 'subject-matter or activities may be excluded from patentability under Article 52(2) and (3) EPC even where they have practical utility' (headnote III), thus ruling out the utility of an invention as a decisive patentability criterion.
295. Under the European Patent Convention, see for instance Article 57 EPC.
296. Trade secret definition. http://www.law.cornell.edu/uscode/18/1839.html.
297. Common issues and challenges in prosecuting trade secret and economic espionage act cases. U.S. Attorneys' Bulletin, November 2009.
298. Uniform Trade Secrets Act (UTSA). http://www.ndasforfree.com/UTSA.html.
299. Uniform Trade Secrets Act. http://euro.ecom.cmu.edu/program/law/08-732/TradeSecrets/utsa.pdf.
300. Economic Economic Espionage Act of 1996, http://www.economicespionage.com/EEA.html.
301. Non-Disclosure Agreements (NDAs) To Protect Your Intellectual Property. http://management.about.com/cs/ipandpatents/a/NDA062199.htm.
302. Non-Compete clause. http://www.absoluteastronomy.com/topics/Non-compete_clause.
303. Are non-compete agreements enforceable in California? . http://www.toplawfirm.com/noncompete%20agreements.html.
304. Trademark definition. http://encyclopedia2.thefreedictionary.com/trademark.
305. World Intellectual Property Organization. http://www.wipo.int/portal/index.html.en.
306. Trademark Basic Fact Sheets. http://www.inta.org/TrademarkBasics/FactSheets/Pages/FactSheets.aspx.
307. How long does it take for a trademark application to mature to a trademark registration? . http://www.registeringatrademark.com/time-for-registration.shtml.
308. Leahy-Smith America Invents Act Implementation . Text of H.R. 1249: Leahy-Smith America Invents Act . http://www.govtrack.us/congress/billtext.xpd?bill=h112-1249.
309. The Leahy Smith America The Leahy Smith America Invents Act Patent Reform of. Presentation made to Tengion Inc 2011, by Ginger Dreger Esq., Arnold & Porter LLP, 1801 Page Mill Road, Suite 110, Palo Alto, CA 94304.
310. What the America Invents Act Means for the Small Inventor . http://www.cio.com/article/691181/What_the_America_Invents_Act_Means_for_the_Small_Inventor?source=rss_news.